As a leader in the RNAi field, Tekmira owns a portfolio of patents and patent applications directed to LNP inventions, the formulation and manufacture of LNP-based pharmaceuticals, chemical modification of RNAi molecules, and RNAi drugs and processes directed at particular disease indications.
Tekmira's technology is protected within an extensive global intellectual property portfolio comprised of approximately 120 active cases, with approximately 55 issued patents and allowed patent applications.
More information about Tekmira's intellectual property portfolio can be found in the section entitled "Patents and Proprietary Rights" in Tekmira's current annual report on Form 20-F, which is available on the Financial Information page on this website as well as at www.sedar.com and www.sec.gov/edgar.